Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65

David C. Seldin, Jennifer J. Anderson, Martha Skinner, Karim Malek, Daniel G. Wright, Karen Quillen, Kathleen Finn, Betul Oran, Vaishali Sanchorawala

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

Recently, protocols using high-dose melphalan chemotherapy and autologous peripheral blood stem cell transplantation (HDM/SCT) have been developed for the treatment of patients with immunoglobulin light chain (AL) amyloidosis. Although peritransplantation mortality is greater than for other hematologic diseases, treatment leads to durable hematologic complete responses, improvements in organ function and quality of life, and extended survival in a substantial proportion of patients. To determine whether this treatment can be applied to older patients, we have analyzed HDM/SCT treatment outcomes for 65 patients (aged 65 years or older) with AL amyloidosis compared with outcomes for 280 younger patients. For patients over age 65 years who meet the same eligibility criteria as younger patients, toxicity, hematologic remission rate, and survival were not significantly different from those observed in younger patients, indicating that older patients should not be excluded a priori from consideration for HDM/SCT treatment.

Original languageEnglish (US)
Pages (from-to)3945-3947
Number of pages3
JournalBlood
Volume108
Issue number12
DOIs
StatePublished - Dec 1 2006

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65'. Together they form a unique fingerprint.

  • Cite this

    Seldin, D. C., Anderson, J. J., Skinner, M., Malek, K., Wright, D. G., Quillen, K., Finn, K., Oran, B., & Sanchorawala, V. (2006). Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. Blood, 108(12), 3945-3947. https://doi.org/10.1182/blood-2006-06-029728